Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 52-Week Low – Should You Sell?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report)’s share price reached a new 52-week low on Tuesday. The company traded as low as $27.10 and last traded at $27.57, with a volume of 356,063 shares. The stock had previously closed at $28.01.

Analysts Set New Price Targets

A number of brokerages have issued reports on IONS. BMO Capital Markets upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $54.00 to $66.00 in a research report on Thursday, October 22nd. Raymond James Financial reissued an “outperform” rating and set a $54.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, November 9th. Barclays decreased their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating on the stock in a report on Wednesday, September 9th. Morgan Stanley lowered their price target on Ionis Pharmaceuticals from $104.00 to $75.00 and set an “overweight” rating for the company in a research report on Tuesday, November 10th. Finally, Wells Fargo & Company dropped their price objective on shares of Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, November 10th. Nineteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $75.71.

Read Our Latest Stock Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 3.42, a current ratio of 5.43 and a quick ratio of 7.73. The company has a market cap of $4.49 billion, a PE ratio of -8.15 and a beta of 0.43. The business has a fifty day simple moving average of $43.05 and a two-hundred day simple moving average of $64.30.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The business had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same period in the prior year, the firm posted ($0.80) earnings per share. The company’s quarterly revenue was up 54.8% on a year-over-year basis. Research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current year.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 5,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were bought at an average cost of $29.64 per share, with a total value of $148,200.00. Following the completion of the acquisition, the director owned 27,000 shares in the company, valued at $800,280. This trade represents a 22.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Shannon L. Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president directly owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This trade represents a 7.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of IONS. Aquatic Capital Management LLC raised its stake in shares of Ionis Pharmaceuticals by 39.9% during the 3rd quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock worth $2,659,000 after buying an additional 16,980 shares during the period. Worldquant Millennium Advisors LLC grew its holdings in Ionis Pharmaceuticals by 48.2% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 72,585 shares of the company’s stock valued at $3,241,000 after buying an additional 23,609 shares in the last quarter. Great Point Partners LLC acquired a new stake in Ionis Pharmaceuticals during the third quarter worth about $18,753,000. Entropy Technologies LP raised its position in shares of Ionis Pharmaceuticals by 36.6% during the 3rd quarter. Entropy Technologies LP now owns 50,303 shares of the company’s stock valued at $2,246,000 after buying an additional 13,488 shares during the period. Finally, Jump Financial LLC lifted its stake in shares of Ionis Pharmaceuticals by 54.0% in the 3rd quarter. Jump Financial LLC now owns 471,682 shares of the company’s stock valued at $21,061,000 after purchasing an additional 165,352 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Read More

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.